Skip to main content

Table 3 Simulated medical costs and life-day gained of overall treatment pathway for DLBCL (n = 4880)

From: Treatment cost and life expectancy of diffuse large B-cell lymphoma (DLBCL): a discrete event simulation model on a UK population-based observational cohort

  N 5-year time horizon N 15-year time horizon N Lifetime horizon
Cost (£),
mean (95 % CI)
Life-days,
mean (95 % CI)
Cost (£),
mean (95 % CI)
Life-days,
mean (95 % CI)
Cost (£),
mean (95 % CI)
Life-days,
mean (95 % CI)
Total 4880 18,096 (18,078–18,114) 1021 (1019–1022) 4880 18,396 (18,377–18,415) 2307 (2304–2310) 4880 18,396 (18,377–18,415) 3667 (3661–3672)
Treated 3892 21,712 (21,692–21,732) 1272 (1271–1273) 3892 22,122 (22,101–22,142) 2884 (2881–2887) 3892 22,122 (22,101–22,142) 4589 (4582–4596)
First-line only 3346 17,994 (17,985–18,003) 1300 (1299–1301) 3316 18,088 (18,078–18,097) 2990 (2987–2994) 3316 18,088 (18,078–18,097) 4718 (4711–4725)
Second-line plus
 With ASCT 154 78,273 (78,224–78,322) 1620 (1617–1622) 167 79,131 (79,084–79,178) 3705 (3692–3719) 167 79,131 (79,084–79,178) 6837 (6797–6877)
 Without ASCT 392 31,209 (31,168–31,251) 889 (886–892) 409 31,471 (31,430–31,512) 1688 (1680–1696) 409 31,471 (31,430–31,512) 2628 (2610–2646)
 Not treated 988 2930 (2918–2942) 30 (29–31) 988 2930 (2918–2942) 30 (29–31) 988 2930 (2918–2942) 30 (29–31)
  1. ASCT autologous stem-cell transplant